Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2005;45:545-551
Published online before print February 21, 2005, doi: 10.1161/01.HYP.0000157409.88971.fc
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
45/4/545    most recent
01.HYP.0000157409.88971.fcv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsuda, M.
Right arrow Articles by Horiuchi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsuda, M.
Right arrow Articles by Horiuchi, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ESTRADIOL
Related Collections
Right arrow ACE/Angiotension receptors
Right arrow Pathophysiology

(Hypertension. 2005;45:545.)
© 2005 American Heart Association, Inc.


Original Articles

Inhibitory Effects of AT1 Receptor Blocker, Olmesartan, and Estrogen on Atherosclerosis Via Anti-Oxidative Stress

Masahiro Tsuda; Masaru Iwai; Jian-Mei Li; Huan-Sheng Li; Li-Juan Min; Ayumi Ide; Midori Okumura; Jun Suzuki; Masaki Mogi; Hiromichi Suzuki; Masatsugu Horiuchi

From the Department of Molecular and Cellular Biology (M.T., M.I., J.-M.L., H.-S.L., L.-J.M., A.I., M.O., J.S., M.M., M.H.), Division of Medical Biochemistry and Cardiovascular Biology, Ehime University School of Medicine, Shigenobu, Ehime, Japan; and the Department of Nephrology (M.T., H.S.), Saitama Medical School, Moroyama, Saitama, Japan.

Correspondence to Masatsugu Horiuchi, MD, PhD, FAHA, Department of Molecular and Cellular Biology, Division of Medical Biochemistry and Cardiovascular Biology, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan. E-mail horiuchi{at}m.ehime-u.ac.jp

Abstracts— The present study explored the possibility that estrogen enhances the inhibitory effect of an angiotensin II type-1 (AT1) receptor blocker (ARB), olmesartan, on atherosclerosis, focusing on oxidative stress using apolipoprotein E knockout mice (ApoEKO). After 6 weeks on a high-cholesterol diet, marked atherosclerotic lesion formation with an increase in oxidative stress, such as superoxide production, NAD(P)H oxidase activity and expression of p47phox mRNA and rac-1 mRNA, were observed in the proximal aorta in both male and female ApoEKO mice, whereas these changes were less marked in female mice. Ovariectomy enhanced these parameters, the changes of which were reversed by 17ß-estradiol (80 µg/kg per day) replacement. Treatment with olmesartan (3 mg/kg per day) significantly inhibited oxidative stress and atherosclerosis, whereas its inhibitory effects were more marked in female than in male or ovariectomized mice. Smaller doses of olmesartan (0.5 mg/kg per day) or 17ß-estradiol (20 µg/kg per day) did not influence atherosclerosis and oxidative stress in ovariectomized mice, whereas co-administration of olmesartan and 17ß-estradiol at these doses attenuated these parameters. An angiotensin-converting enzyme (ACE) inhibitor, temocapril, also inhibited atherosclerotic changes similarly to olmesartan. Moreover, angiotensin II–mediated activation of NAD(P)H oxidase in cultured vascular smooth muscle cells was attenuated by 17ß-estradiol. These results indicate that estrogen and an ARB synergistically attenuate atherosclerosis at least partly via inhibition of oxidative stress.


Key Words: atherosclerosis • estrogen • oxidative stress • receptors, angiotensin II




This article has been cited by other articles:


Home page
HypertensionHome page
W. J. Welch
Angiotensin II-Dependent Superoxide: Effects on Hypertension and Vascular Dysfunction
Hypertension, July 1, 2008; 52(1): 51 - 56.
[Full Text] [PDF]


Home page
Eur Heart JHome page
L. Guasti, F. Marino, M. Cosentino, R. C. Maio, E. Rasini, M. Ferrari, L. Castiglioni, C. Klersy, G. Gaudio, A. M. Grandi, et al.
Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up
Eur. Heart J., May 1, 2008; 29(9): 1118 - 1126.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
S. Hagita, M. Osaka, K. Shimokado, and M. Yoshida
Oxidative Stress in Mononuclear Cells Plays a Dominant Role in Their Adhesion to Mouse Femoral Artery After Injury
Hypertension, March 1, 2008; 51(3): 797 - 802.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Zadelaar, R. Kleemann, L. Verschuren, J. de Vries-Van der Weij, J. van der Hoorn, H. M. Princen, and T. Kooistra
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1706 - 1721.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H. Kanamori, G. Takemura, Y. Li, H. Okada, R. Maruyama, T. Aoyama, S. Miyata, M. Esaki, A. Ogino, M. Nakagawa, et al.
Inhibition of Fas-associated apoptosis in granulation tissue cells accompanies attenuation of postinfarction left ventricular remodeling by olmesartan
Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2184 - H2194.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
P. L HARKONEN and H. K. VAANANEN
Monocyte-Macrophage System as a Target for Estrogen and Selective Estrogen Receptor Modulators
Ann. N.Y. Acad. Sci., November 1, 2006; 1089(1): 218 - 227.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
J. A. Miller, D. Z. Cherney, J. A. Duncan, V. Lai, K. D. Burns, C. R.J. Kennedy, J. Zimpelmann, W. Gao, D. C. Cattran, and J. W. Scholey
Gender Differences in the Renal Response to Renin-Angiotensin System Blockade
J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2554 - 2560.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
S. Kumar, S. Savitz, G. Schlaug, L. Caplan, and M. Selim
Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk
Neurology, April 25, 2006; 66(8): 1153 - 1158.
[Abstract] [Full Text] [PDF]